What drugs does RELIANCE LIFE SCI make?

RELIANCE LIFE SCI has 2 FDA-approved drugs.

What therapeutic areas does RELIANCE LIFE SCI focus on?

RELIANCE LIFE SCI focuses primarily on Oncology.

← Back

Data updated: Jun 28, 2026

RELIANCE LIFE SCI

Generics

Oncology

RELIANCE LIFE SCI is a generic drug manufacturer focused on Oncology.

2022

Since

Drugs

Trials

New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →

Jan 20, 2027 — Foundayo (orforglipron)

RELIANCE LIFE SCI's Key Drugs

RELIANCE LIFE SCI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

RELIANCE LIFE SCI's Recent FDA Approvals

RELIANCE LIFE SCI secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

BORTEZOMIB NDA

2024-08-26

bortezomib

1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

RELIANCE LIFE SCI's Therapeutic Areas

RELIANCE LIFE SCI's approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%

1 drugs

RELIANCE LIFE SCI's Top Competitors

RELIANCE LIFE SCI's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.